Revenue
2022
2023
2024
2025
Kura Oncology, Inc. (KURA)
Price$13.25Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M | $60.4M | $47.8M | $46.8M | $26.4M | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M | $91.9M | $67.5M | $62.9M | $36.1M | $28.4M | $23.9M | — | — | — | — | — | — | — | — |
| Operating income | −$303.6M | −$193.2M | −$165.8M | −$139.9M | — | — | — | — | — | — | — | −$23,907 | −$22,734 | −$22,341 | −$23,440 | −$20,509 | — | — | — |
| Operating margin | −449.94% | −358.55% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$302.6M | −$192.3M | −$165.0M | −$139.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −448.41% | −356.97% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$278.7M | −$174.0M | −$152.6M | −$135.8M | −$130.5M | −$89.6M | −$63.1M | −$60.4M | −$35.4M | −$27.6M | −$22.6M | −$30,734 | −$28,611 | −$27,315 | −$27,040 | −$22,395 | −$19,996 | −$33,623 | −$14,977 |
| Net profit margin | −412.95% | −322.89% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | -$1.51 | -$1.72 | -$1.52 | -$1.47 | -$2.28 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.00 | — | — | — |
| Diluted EPSper diluted share | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | -$1.51 | -$1.72 | -$1.52 | -$1.47 | -$2.28 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.00 | — | — | — |
Owners
Reported shareholders
11.81%of listed shares
BlackRock, Inc.10.51M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 11.81%10.51M shares |
MONTANOVA CAPITAL, LLC | 9.64%8.58M shares |
BVF INC/IL | 9.49%8.45M shares |
STATE STREET CORP | 5.99%5.33M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.40%3.92M shares |
ARMISTICE CAPITAL, LLC | 4.13%3.68M shares |
AQR CAPITAL MANAGEMENT LLC | 3.51%3.13M shares |
GOLDMAN SACHS GROUP INC | 2.55%2.27M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.51%2.23M shares |
ALETHEA CAPITAL MANAGEMENT, LLC | 2.44%2.17M shares |
Prosight Management, LP | 2.27%2.02M shares |
Deep Track Capital, LP | 2.22%1.98M shares |
RENAISSANCE TECHNOLOGIES LLC | 1.87%1.66M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.59%1.41M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.50%1.33M shares |
NAN FUNG TRINITY (HK) LTD | 1.32%1.17M shares |
Qube Research & Technologies Ltd | 1.32%1.17M shares |
DIMENSIONAL FUND ADVISORS LP | 1.31%1.17M shares |
BANK OF AMERICA CORP /DE/ | 1.31%1.16M shares |
MORGAN STANLEY | 1.30%1.16M shares |
Percentages use 88.95M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 · 10b5-1 | Leoni MollieChief Medical Officer | SellCommon Stock | 84.9K | $9.82 | $834.0K | 182.3K |
| May 21, 2026Form 4 · 10b5-1 | Powl Brian T.Chief Commercial Officer | SellCommon Stock | 10.0K | $11.00 | $110.0K | 173.6K |
| May 19, 2026Form 4 · 10b5-1 | FORD KATHLEENChief Operating Officer | SellCommon Stock | 2.3K | $9.08 | $20.5K | 153.6K |
| May 19, 2026Form 4 · 10b5-1 | Powl Brian T.Chief Commercial Officer | SellCommon Stock | 339 | $9.21 | $3.1K | 183.6K |
| May 18, 2026Form 4 · 10b5-1 | Bair Teresa BrophyChief Legal Officer | SellCommon Stock | 2.3K | $9.38 | $21.2K | 226.9K |